Christian Rosas-Salazar1, Tebeb Gebretsadik2, Kecia N Carroll3, Sara Reiss4, Nancy Wickersham4, Emma K Larkin4, Kristina M James4, E Kathryn Miller5, Larry J Anderson6, Tina V Hartert7. 1. Division of Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, Tennessee. ; Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University , Nashville, Tennessee. 2. Department of Biostatistics, Vanderbilt University School of Medicine , Nashville, Tennessee. ; Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University , Nashville, Tennessee. 3. Division of General Pediatrics, Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, Tennessee. ; Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University , Nashville, Tennessee. 4. Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University , Nashville, Tennessee. 5. Division of Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, Tennessee. 6. Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta , Atlanta, Georgia . 7. Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine , Nashville, Tennessee. ; Vanderbilt Center for Asthma and Environmental Health Sciences Research, Vanderbilt University , Nashville, Tennessee.
Abstract
Background: Infants with lower respiratory tract infections (LRTIs) are at an increased risk of developing childhood wheezing illnesses (including asthma), but it is not currently possible to predict those at risk for these long-term outcomes. The current objective was to examine whether urine levels of club cell 16-kDa secretory protein (CC16) at the time of an infant LRTI are associated with the development of childhood wheezing illnesses. Methods: Prospective study of 133 previously healthy infants enrolled during a healthcare visit for a LRTI and followed longitudinally for childhood wheezing illnesses. Urine levels of CC16 at the time of enrollment were measured after validating a commercially available enzyme-linked immunosorbent assay kit for serum. The outcome of interest was parental report of subsequent childhood wheeze (defined as ≥1 episode of wheezing following the initial LRTI) at the 1-year follow-up visit. Logistic regression was used for the main analysis. Results: The median (interquartile range) urine levels of CC16 (ng/mg of creatinine) at the time of an infant LRTI were 11.1 (7.7-20.1) for infants with subsequent childhood wheeze and 13.4 (8.3-61.1) for those without (p = 0.11). In the main multivariate analysis using a logarithmic transformation of the urine levels of CC16, a twofold increase in urine levels of CC16 was associated with ∼30% decreased odds (OR = 0.74 [95% confidence interval (CI) 0.56-0.98], p = 0.04) of subsequent childhood wheeze after adjustment for potential confounders. Conclusions: An inverse association was found between urine levels of CC16 at the time of an infant LRTI and the odds of subsequent childhood wheeze. Urine CC16 may be a useful biomarker of the development of childhood wheezing illnesses after LRTIs in infancy.
Background: Infants with lower respiratory tract infections (LRTIs) are at an increased risk of developing childhood wheezing illnesses (including asthma), but it is not currently possible to predict those at risk for these long-term outcomes. The current objective was to examine whether urine levels of club cell 16-kDa secretory protein (CC16) at the time of an infant LRTI are associated with the development of childhood wheezing illnesses. Methods: Prospective study of 133 previously healthy infants enrolled during a healthcare visit for a LRTI and followed longitudinally for childhood wheezing illnesses. Urine levels of CC16 at the time of enrollment were measured after validating a commercially available enzyme-linked immunosorbent assay kit for serum. The outcome of interest was parental report of subsequent childhood wheeze (defined as ≥1 episode of wheezing following the initial LRTI) at the 1-year follow-up visit. Logistic regression was used for the main analysis. Results: The median (interquartile range) urine levels of CC16 (ng/mg of creatinine) at the time of an infant LRTI were 11.1 (7.7-20.1) for infants with subsequent childhood wheeze and 13.4 (8.3-61.1) for those without (p = 0.11). In the main multivariate analysis using a logarithmic transformation of the urine levels of CC16, a twofold increase in urine levels of CC16 was associated with ∼30% decreased odds (OR = 0.74 [95% confidence interval (CI) 0.56-0.98], p = 0.04) of subsequent childhood wheeze after adjustment for potential confounders. Conclusions: An inverse association was found between urine levels of CC16 at the time of an infant LRTI and the odds of subsequent childhood wheeze. Urine CC16 may be a useful biomarker of the development of childhood wheezing illnesses after LRTIs in infancy.
Authors: S E Daniels; S Bhattacharrya; A James; N I Leaves; A Young; M R Hill; J A Faux; G F Ryan; P N le Söuef; G M Lathrop; A W Musk; W O Cookson Journal: Nature Date: 1996-09-19 Impact factor: 49.962
Authors: Kecia N Carroll; Tebeb Gebretsadik; Patricia Minton; Kimberly Woodward; Zhouwen Liu; E Kathryn Miller; John V Williams; William D Dupont; Tina V Hartert Journal: J Allergy Clin Immunol Date: 2012-02-14 Impact factor: 10.793
Authors: Jing Zhai; Michael Insel; Kenneth J Addison; Debra A Stern; William Pederson; Alane Dy; Joselyn Rojas-Quintero; Caroline A Owen; Duane L Sherrill; Wayne Morgan; Anne L Wright; Marilyn Halonen; Fernando D Martinez; Monica Kraft; Stefano Guerra; Julie G Ledford Journal: Am J Respir Crit Care Med Date: 2019-02-01 Impact factor: 21.405
Authors: Kedir N Turi; Lindsey Romick-Rosendale; Tebeb Gebretsadik; Miki Watanabe; Steven Brunwasser; Larry J Anderson; Martin L Moore; Emma K Larkin; Ray Stokes Peebles; Tina V Hartert Journal: Metabolomics Date: 2018-10-01 Impact factor: 4.290
Authors: Paloma I Beamer; Walter T Klimecki; Miranda Loh; Yoshira Ornelas Van Horne; Anastasia J Sugeng; Nathan Lothrop; Dean Billheimer; Stefano Guerra; Robert Clark Lantz; Robert A Canales; Fernando D Martinez Journal: Int J Environ Res Public Health Date: 2016-10-04 Impact factor: 3.390
Authors: Sarah J D Nauwelaerts; Koen De Cremer; Natalia Bustos Sierra; Mathieu Gand; Dirk Van Geel; Maud Delvoye; Els Vandermassen; Jordy Vercauteren; Christophe Stroobants; Alfred Bernard; Nelly D Saenen; Tim S Nawrot; Nancy H C Roosens; Sigrid C J De Keersmaecker Journal: Int J Environ Res Public Health Date: 2022-07-12 Impact factor: 4.614